

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



廣州白雲山醫葯集團股份有限公司

GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS CO., LTD.

(a joint stock company with limited liability established in the People's Republic of China)

(H Share Stock Code: 0874)

APPOINTMENT OF INDEPENDENT FINANCIAL ADVISER

Reference is made to the announcement of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (the “**Company**”) dated 15 January 2016 (the “**Announcement**”) in relation to the extension of the effective period of (i) the shareholders’ resolutions relating to the Proposed Placing, revised as disclosed in the announcements of the Company dated 28 October 2015 and 26 November 2015 respectively (the “**Revised Proposed Placing**”); and (ii) the authorisation granted to the Board and persons authorised by the Board to handle matters relating to the Revised Proposed Placing. Unless otherwise defined, capitalised terms used in this announcement shall have the same meanings as those defined in the Announcement.

Grand Vinco Capital Limited has been appointed as the independent financial adviser to advise the independent board committee and the independent shareholders of the Company on the Extension Resolutions, and such appointment has been approved by the independent board committee of the Company. The advice of Grand Vinco Capital Limited to the independent board committee and the independent shareholders of the Company will be included in the circular in relation to the Extension Resolutions, which is expected to be despatched to the shareholders of the Company on or before 5 February 2016.

Grand Vinco Capital Limited, a wholly-owned subsidiary of Vinco Financial Group Limited (stock code: 8340), is a licensed corporation to carry out type 1 (dealing in securities) and type 6 (advising on corporate finance) regulated activities under the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The Board of
**Guangzhou Baiyunshan Pharmaceutical
Holdings Company Limited**

Guangzhou, the PRC, 26 January 2016

As at the date of this announcement, the Board comprises Mr. Li Chuyuan, Mr. Chen Mao, Ms. Liu Juyan, Ms. Cheng Ning, Mr. Ni Yidong, Mr. Wu Changhai and Mr. Wang Wenchu as executive directors, and Mr. Wong Lung Tak Patrick, Mr. Qiu Hongzhong, Mr. Chu Xiaoping and Mr. Jiang Wenqi as independent non-executive directors.